Profluent launches the first AI design gene editor OpenCRISPR-1

Profluent, a protein design company with artificial intelligence as its core technology, has successfully edited the human genome using OpenCRISPR-1. OpenCRISPR-1 is the world's first fully AI-designed and open-source gene editor, making it a major breakthrough in the industry.

Profluent trained its technology on a large language model using a vast dataset of biological sequences and contextual information, generating millions of CRISPR-like proteins that do not exist naturally. This achievement greatly expands the known CRISPR family, setting a new milestone in the field of gene editing and bringing hope for the accelerated development of precise therapies for a range of genetic diseases.

Profluent's technology, by enabling faster and more precise genetic modifications, has the potential to reshape the landscape of medical research. CRISPR technology has already begun to change the way genetic diseases such as sickle cell disease are treated. Compared to currently available gene editors that are limited by natural evolution, AI-generated gene editors demonstrate greater adaptability and potential functionality.

OpenCRISPR-1, as the core of this breakthrough, is an AI-generated gene editor composed of a protein similar to Cas9 and guide RNA. Despite having hundreds of mutations different from any natural protein, it exhibits activity and specificity comparable to or higher than the widely used gene editor SpCas9. Profluent has decided to provide OpenCRISPR-1 free of charge for ethical research and commercial purposes, demonstrating their commitment to promoting the widespread adoption of this transformative technology.

Ali Madani, co-founder and CEO of Profluent, said, "Attempting to edit human DNA using biologically engineered systems designed by artificial intelligence is a scientific feat. Our success heralds a future where AI will be able to precisely design various customized disease treatments."

This development carries profound significance. By expanding the scope of the CRISPR family and releasing foundational molecules that can be further engineered, Profluent's AI-driven approach provides broader access and lower costs for gene editing therapies. This has the potential to accelerate the development of thousands of currently incurable genetic disease treatments.

However, scientists caution that while AI-generated gene editors hold tremendous potential, they are unlikely to have a significant impact on healthcare in the short term. Feodor Urnov, a gene editing pioneer at the University of California, Berkeley, believes that there are still barriers, such as cost, from preclinical research to application in patients.

Nevertheless, the rapid development of generative AI technology allows us to glimpse the possibilities of a future where drugs and treatment plans can be rapidly customized for individuals. James Fraser, a professor at the University of California, San Francisco, noted, "This system has learned how to create them from nature, but they are entirely new."

Profluent's breakthrough marks the beginning of a new era in gene editing, where AI plays a central role in designing tools that can fundamentally transform medicine. With continued technological advancements, we are getting closer to a world where precise treatments for genetic diseases are more accessible and effective than ever before.